"We are going to move to Estee Palm's growth engine"

there is no new API order,

A former NH Investment & Securities researcher said December 12 that "
Estee Palm Change Change The current price Close Close [19659000] Turnover of 47.9 billion won and a result of exploitation of 8.4 billion won was recorded in the same quarter of the previous year Compared to 15.6% and 56.4%, respectively, compared to the previous quarter, but it is estimated that it has increased by 69% and 5081.9% compared to the previous quarter. "

Change Change The current price Close [19659000] Close [19659000] is a new growth engine, Oligo API, this is the case of Imetelstat. Clinical trials have been delayed due to the late entry of clinical trials. The Methylstat has announced plans to expand Phase 2 clinical trials for patients with multiple myelosuppression (MDS) in August of last year, and plans to enter Phase 3 in August.

"We expect Orion API sales to reach 27.7 billion won in 2018 and 38.3 billion won in 2019."

The new plant should be launched in the 4th quarter. Recently, the RNA market is developing rapidly, and it is expected that the FDA (Food and Drug Administration) Patisiran (HATTR amyloidosis) will be obtained for the first time as a siRNA therapeutic drug in August. of this year. Also on Nov. 12, it is expected to be listed on KOSDAQ's Orlyx of Korea.

Estee Palm Change Change The Current Price Close

is a company of CMO (Contract Manufacturing) of Ollyx, established in May by the company. Institute of Technology of the United States.